Clinical trials: Adebrelimab
Urothelial Carcinoma, Advanced Urothelial Carcinoma
Phase II Study of Trastuzumab Rezetecan or in Combination With Adebrelimab in HER2-Expressing Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC)
This is a multicenter, open-label, Phase II clinical trial to evaluate the efficacy and safety of Trastuzumab Rezetecan (SHR-A1811) or in combination with Adebrelimab (SHR-1316) for HER2-expressing locally advanced or metastatic…
- Conditions
- Urothelial Carcinoma, Advanced Urothelial Carcinoma, Urothelial Carcinoma Recurrent
- Trial name
- TRAIN-UC-01 (NCT07241793)
- Testing
- Adebrelimab, Trastuzumab Rezetecan
- Where
- 6 sites in China
- Volunteers
- 96 people
- Sponsor
- Sun Yat-sen University
Rectal Adenocarcinoma
The Efficacy and Safety of Short-course Radiation Combined With Adebrelimab and CAPEOX Neo-adjuvant Therapy for Organ-retention in Patients With MSS/pMMR Ultra Low Rectal Adenocarcinoma
To evaluate the efficacy, safety and organ retention rate of short-course radiation combined with Adebrelimab and CAPEOX neoadjuvant therapy in patients with MSS/pMMR ultra low rectal adenocarcinoma.
- Trial name
- NCT06266832
- Testing
- Adebrelimab, Oxaliplatin, Capecitabine
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sir Run Run Shaw Hospital
Breast Cancer, HR+/HER2- Breast Cancer
To Evaluate the Efficacy of Adebrelimab Combined With Chemotherapy After HIFU Induction Neoadjuvant Therapy HR+/HER2- Breast Cancer
To explore the efficacy and safety of adebrelimab combined with chemotherapy (epirubicin + cyclophosphamide →docetaxel) neoadjuvant therapy early HR+/HER2- breast cancer with high risk factors after the induction treatment of…
- Trial name
- NCT06470633
- Testing
- Adebrelimab, High Intensity Focused Ultrasoun（HIFU）, Cyclophosphamide
- Volunteers
- 29 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Locally Advanced Gastric Adenocarcinoma
Adebrelimab Combined With SOX Regimen in Preoperative Neoadjuvant Transformation Therapy for Locally Advanced Gastric Adenocarcinoma
Abstract Objective: Adebrelimab is a PD-L1 inhibitor. The aim of this trial is to evaluate the safety and efficacy of adebrelimab combined with SOX regimen for preoperative neoadjuvant therapy in locally advanced gastric…
- Trial name
- NCT06192186
- Testing
- Adebrelimab combined with SOX regimen
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Yang Jianjun, PhD
ESCC
Adebrelimab Plus Full-course Neoadjuvant Therapy for Resectable Locally Advanced ESCC (Phase 2)
This is a prospective, single-center, randomized phase 2 study of adebrelimab plus full-course neoadjuvant therapy in resectable locally advanced esophageal squamous cell carcinoma.
- Trial name
- NAT-ESCC-01 (NCT07584031)
- Testing
- Combination therapy with chemotherapy and immunotherapy, Surgery
- Volunteers
- 200 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Nasopharyngeal Carcinoma, Nasopharyngeal Cancer
Adebrelimab and Chemoradiotherapy in High-risk LANPC
This trial aims to study the role of Adebrelimab combined with induction chemotherapy plus concurrent chemoradiotherapy (IC+CCRT) for high-risk locoregionally advanced nasopharyngeal carcinoma(LANPC).
- Trial name
- NCT06349889
- Testing
- Adebrelimab
- Where
- 4 sites in China
- Volunteers
- 50 people
- Sponsor
- Sun Yat-sen University
Esophageal Squamous Cell Carcinoma (ESCC)
Adebrelimab Combined With Neoadjuvant Chemoradiotherapy for Esophageal Squamous Cell Carcinoma
This study aims to systematically evaluate the safety and efficacy of adalimumab combined with paclitaxel, carboplatin, and short-course radiotherapy in the neoadjuvant treatment of esophageal squamous cell carcinoma.
- Trial name
- ANCRE (NCT07595770)
- Testing
- • Adebrelimab and nab-paclitaxel, carboplatin in Combination With radiotherapy
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Adebrelimab (SHR-1316), Bevacizumab
Efficacy and Safety of Low-dose Bevacizumab Plus Adebrelimab Combined With Transarterial Chemoembolization Followed by Hepatic Arterial Infusion Chemotherapy (TACE-HAIC) as First-line Treatment for Unresectable Hepatocellular Carcinoma: A Single-arm Phase 2 Trial
his is a single-arm, phase II clinical study evaluating the efficacy and safety of low-dose bevacizumab (7.5 mg/kg, Q3W) plus adebrelimab (1200 mg, Q3W) combined with transarterial chemoembolization (TACE) followed by hepatic…
- Conditions
- Adebrelimab (SHR-1316), Bevacizumab, Hepatocellular Carcinoma (HCC)
- Trial name
- NCT07543783
- Testing
- Transarterial Chemoembolization (TACE), Hepatic Arterial Infusion Chemotherapy (HAIC, FOLFOX), Adebrelimab
- Volunteers
- 38 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Platinum-resistant Ovarian Cancer (PROC), Immunotherapy
Adebrelimab Combined with Non-platinum Chemotherapy and Fuzuloparib in Recurrent Platinum-resistant Ovarian Cancer
The investigators explore the efficacy and safety of adebrelimab (PD-L1 inhibitor) plus Non-platinum chemotherapy and Fuzuloparib (PARP inhibitor) induction therapy followed by maintenance therapy with adebrelimab plus fluzoparib…
- Trial name
- NCT06600841
- Testing
- Immunotherapy（Adebrelimab）
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Fujian Cancer Hospital
Locally Advanced Resectable Rectal Cancer
Exploratory Study of Short-Course Radiotherapy Followed by Adebrelimab Combined With Chemotherapy for Organ Preservation in Locally Advanced Rectal Cancer
This prospective, single-arm, exploratory clinical study aims to evaluate the efficacy and safety of short-course radiotherapy (SCRT) sequentially followed by adebrelimab combined with chemotherapy as an organ-preservation…
- Trial name
- NCT07905950
- Testing
- Adebrelimab
- Where
- China
- Volunteers
- 155 people
- Sponsor
- Henan Cancer Hospital
Non Small Cell Lung Cancer
A Study of SHR-A1811 Combined With Adebrelimab for the First-line HER2-overexpressing Non-squamous Non-small Cell Lung Cancer
This is a randomized, open-label, multicenter, phase 3 clinical study comparing the efficacy and safety of SHR-A1811 in combination with Adebrelimab versus platinum-based doublet chemotherapy in combination with Tislelizumab as…
- Trial name
- NCT07896005
- Testing
- SHR-A1811 Injection, Adebrelimab Injection, Tislelizumab Injection
- Where
- 2 sites in China
- Volunteers
- 436 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Locally Advanced Gastric or Gastroesophageal Junction Cancer
Clinical Study of Adebrelimab Therapy in the Perioperative Treatment of Gastric Cancer or Gastroesophageal Junction Cancer
This study was a randomized, double-blind, multi-center phase III clinical trial to evaluate the event-free survival (EFS) of Adebrelimab with S-1 and oxaliplatin versus placebo combined with S-1 and oxaliplatin, and to evaluate…
- Trial name
- NCT07522151
- Testing
- Adebrelimab plus S-1 and oxaliplatin, Adebrelimab blank preparation plus S-1 and oxaliplatin.
- Where
- China
- Volunteers
- 874 people
- Sponsor
- Shanghai Shengdi Pharmaceutical Co., Ltd
Advanced Non-small Cell Lung Cancer
Clinical Study of SHR-A1921 Combined With Adebrelimab and SHR-8068 With or Without Carboplatin in the Treatment of Advanced NSCLC
A trial to evaluate the tolerability and efficacy of SHR-A1921 in combination with adbelizumab and SHR-8068 with or without carboplatin in patients with advanced non-small cell lung cancer
- Trial name
- NCT06434103
- Testing
- SHR-A1921；Adebrelimab；SHR-8068；carboplatin
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Resectable Intrahepatic Cholangiocarcinoma With High Risk of Recurrence
Chemotherapy Combined With Adebrelimab and Apatinib as the Perioperative Treatment in Patients With Biliary Tract Cancer
This is a prospective, single-arm exploratory study to evaluate the efficacy and safety of chemotherapy combined with Adebrelimab and Apatinib as the perioperative treatment in Patients With Biliary Tract Cancer.
- Trial name
- NCT06280508
- Testing
- Adebrelimab, Apatinib, Gemcitabine, cisplatin
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Intrahepatic Cholangiocarcinoma (Icc)
Adebrelimab Combined with Irinotecan Liposomes, 5-FU, CF ± Lenvatinib As First-line Treatment for Advanced ICC
This is a multicenter, open label, randomized, two-arm clinical study to observe and evaluate the efficacy and safety of adebrelimab combined with irinotecan liposomes, 5-fluorouracil, calcium folinate ± lenvatinib as first-line…
- Trial name
- NCT06648525
- Testing
- Adebrelimab, Irinotecan liposomes, Lenvatinib
- Where
- China
- Volunteers
- 68 people
- Sponsor
- Harbin Medical University
Advanced or Metastatic Non-small Cell Lung Cancer
Phase III Study of SHR-8068 Combined With Adebrelimab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer
This study is a randomized, open-label, controlled, multicenter Phase III clinical trial to evaluate the efficacy and safety of SHR-8068 combined with adebrelimab and platinum-based chemotherapy versus tislelizumab combined with…
- Trial name
- NCT07170995
- Testing
- SHR-8068，adebelizumab and platinum-based chemotherapy, tislelizumab, and platinum-based chemotherapy
- Where
- China
- Volunteers
- 460 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Breast Cancer
Adebrelimab Combined With Dalpiciclib and Standard Endocrine Therapy for HR+/HER2 - Advanced Breast Cancer
This is a prospective, single-arm, multicenter Phase II study of patients with advanced HR+/HER2- breast cancer who are untreated or have failed previous first-line endocrine therapy。The primary objective of this study was to…
- Trial name
- NCT06149130
- Testing
- Adebrelimab, dalpiciclib
- Where
- China
- Volunteers
- 82 people
- Sponsor
- Tongji Hospital
Rectal Cancer, Advanced Stage Colorectal Cancer
Adebrelimab Injection (PD-L1) Combined With Short Course Radiotherapy and Chemotherapy for Neoadjuvant Therapy of Locally Advanced Rectal Cancer
This study is a multicenter, single arm, prospective study aimed at evaluating the efficacy and safety of adebelimab combined with short course radiotherapy (5 * 5Gy) and chemotherapy as preoperative neoadjuvant therapy for…
- Conditions
- Rectal Cancer, Advanced Stage Colorectal Cancer, Radiotherapy
- Trial name
- NCT06765616
- Testing
- Adebrelimab Injection combined with radiotherapy and chemotherapy
- Where
- China
- Volunteers
- 31 people
- Sponsor
- Feng Tian
Head and Neck Squamous Cell Carcinoma
A Study of Nimotuzumab Plus Adebrelimab With Chemotherapy in Cisplatin-Ineligible Patients With Head And Neck Squamous Cell Carcinoma
This is a prospective, single-arm, Phase Ib/II clinical study to evaluate the safety and efficacy of nimotuzumab combined with adebrelimab and chemotherapy in patients with recurrent and metastatic head and neck squamous cell…
- Trial name
- NCT07105592
- Testing
- Nimotuzumab+Adebrelimab+Chemotherapy
- Where
- China
- Volunteers
- 68 people
- Sponsor
- Fudan University
Pancreatic Ductal Adenocarcinoma (PDAC)
Clinical Study of Radiotherapy Combined With Adebrelimab and NALIRIFOX for Conversion Therapy in Locally Advanced Pancreatic Cancer
This study intends to explore conversion therapy for locally advanced pancreatic cancer (LAPC). The intervention starts with modified stereotactic body radiation therapy (3-day regimen), followed by systemic therapy within 1-2…
- Trial name
- NCT07827053
- Testing
- Adebrelimab (PD-L1 inhibitor), NALIRIFOX, SBRT
- Volunteers
- 36 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine